BBT-207

· Bridge Biotherapeutics, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BBT-207, covering 2025-04-27 to 2025-04-27. Get the full timeline:

Most recent: Clinical Trial Update: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI [Phase 1, Phase 2]

See pricing